IL-23 inhibitors

IL-23 inhibitors are class of biologics that inhibit the P 19 subunit of IL-23 and reduce the activities of the Th17 pathway. 

These agents approved to treat plaque psoriasis include: guselkumab, tildrakizumab, risankizumab and mirkikizumab.

These agents have acceptable safety profiles, and convenient infrequent dosing schedules.

IL-23 inhibitors have no increase in serious infections or malignancy. 

Upper respiratory tract infections and injection site reactions are the most frequent reported adverse reactions. 

Leave a Reply

Your email address will not be published. Required fields are marked *